CO5280075A1 - DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY - Google Patents
DROSPIRENONE FOR HORMONE REPLACEMENT THERAPYInfo
- Publication number
- CO5280075A1 CO5280075A1 CO01003045A CO01003045A CO5280075A1 CO 5280075 A1 CO5280075 A1 CO 5280075A1 CO 01003045 A CO01003045 A CO 01003045A CO 01003045 A CO01003045 A CO 01003045A CO 5280075 A1 CO5280075 A1 CO 5280075A1
- Authority
- CO
- Colombia
- Prior art keywords
- estrogen
- active agent
- drospirenone
- carbolactone
- preg
- Prior art date
Links
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 title abstract 3
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 title abstract 3
- 229960004845 drospirenone Drugs 0.000 title abstract 3
- 238000002657 hormone replacement therapy Methods 0.000 title 1
- 229940011871 estrogen Drugs 0.000 abstract 5
- 239000000262 estrogen Substances 0.000 abstract 5
- 239000013543 active substance Substances 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 2
- 230000002950 deficient Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 210000004696 endometrium Anatomy 0.000 abstract 2
- 229960005309 estradiol Drugs 0.000 abstract 2
- 229930182833 estradiol Natural products 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composición farmacéutica que comprendecomo un primer agente activo, un estrógeno (o derivado natural o sintético del mismo) en cantidades suficientes para tratar enfermedades, desórdenes y síntomas asociados con niveles endógenos deficientes de estrógeno en mujeres, y como un segundo agente activo, 6ß, 7ß, 15ß, 16ß-dimetilen-3-oxo-17a-preg-4-eno-27,17-carbolactona (drospirenona) en cantidades suficientes para proteger el endometrio de los efectos adversos del estrógeno, conjuntamente con un excipiente o portador farmacéuticamente aceptable. Una composición farmacéutica que comprende estradiol como un primer agente activo en cantidades que corresponden a una dosis diaria de 1 a 3 mg para tratar enfermedades, desórdenes y síntomas asociados con niveles endógenos deficientes de estrógeno en mujeres, y como un segundo agente activo 6ß, 7ß, 15ß, 16ß-dimetilen-3-oxo-17a-preg-4-eno-27,17-carbolactona (drospirerona) en cantidades suficientes que corresponden a una dosis diaria de 1 a 3,5 mg para proteger el endometrio de los efectos adversos del estrógeno, junto con un excipiente o portador farrnacéuticamente aceptable.Una preparación farmacéutica multi-fásica que consiste en un número de unidades de dosificación diarias separadamente envasadas e individualmente removibles dispuestas dentro de una unidad de envase destinadas a administración oral durante un periodo de al menos 21 días donde dichas unidades de dosificación diarias comprenden una combinación de estradiol en una cantidad en el rango de desde aproximadamente 0,1 a 5 mg y drospirenona en el rango de desde aproximadamente 0,25 a 6 mg.A pharmaceutical composition comprising as a first active agent, an estrogen (or natural or synthetic derivative thereof) in amounts sufficient to treat diseases, disorders and symptoms associated with endogenous estrogen deficient levels in women, and as a second active agent, 6β, 7ß, 15ß, 16ß-dimethylene-3-oxo-17a-preg-4-eno-27.17-carbolactone (drospirenone) in amounts sufficient to protect the endometrium from the adverse effects of estrogen, together with a pharmaceutically acceptable carrier or excipient . A pharmaceutical composition comprising estradiol as a first active agent in amounts corresponding to a daily dose of 1 to 3 mg to treat diseases, disorders and symptoms associated with endogenous estrogen deficient levels in women, and as a second active agent 6ß, 7ß , 15ß, 16ß-dimethylene-3-oxo-17a-preg-4-eno-27.17-carbolactone (drospirerona) in sufficient amounts corresponding to a daily dose of 1 to 3.5 mg to protect the endometrium from effects adverse effects of the estrogen, together with a pharmaceutically acceptable carrier or excipient. A multi-phase pharmaceutical preparation consisting of a number of separately dosed and individually removable daily dosage units disposed within a container unit intended for oral administration during a period of at least minus 21 days where said daily dosage units comprise a combination of estradiol in an amount in the range of from apr approximately 0.1 to 5 mg and drospirenone in the range of from about 0.25 to 6 mg.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00200183 | 2000-01-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5280075A1 true CO5280075A1 (en) | 2003-05-30 |
Family
ID=38170612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO01003045A CO5280075A1 (en) | 2000-01-18 | 2001-01-17 | DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY |
Country Status (7)
| Country | Link |
|---|---|
| AR (1) | AR035633A1 (en) |
| CO (1) | CO5280075A1 (en) |
| HR (1) | HRP20070360B1 (en) |
| JO (1) | JO2334B1 (en) |
| PE (1) | PE20011051A1 (en) |
| SA (1) | SA01210754B1 (en) |
| UA (2) | UA81388C2 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4426601A1 (en) * | 1994-07-27 | 1996-02-01 | Schering Ag | Use of a combination product containing a competitive progesterone antagonist and a progestogen for the manufacture of a medicament for the treatment of endometriosis or Leiomyomata uteri |
| DE19654609A1 (en) * | 1996-12-20 | 1998-06-25 | Schering Ag | Therapeutic progestogens for the treatment of premenstrual dysphoric disorder |
| RS50262B2 (en) * | 1999-08-31 | 2018-10-31 | Bayer Pharma AG | PHARMACEUTICAL COMBINATION OF ETHINYLESTRADIOL AND DROSPIRENONE FOR ADMINISTRATION AS CONTRACEPTIVE |
-
2001
- 2001-01-11 JO JO200110A patent/JO2334B1/en active
- 2001-01-15 PE PE2001000035A patent/PE20011051A1/en active IP Right Grant
- 2001-01-17 CO CO01003045A patent/CO5280075A1/en not_active Application Discontinuation
- 2001-01-17 AR ARP010100199 patent/AR035633A1/en not_active Application Discontinuation
- 2001-01-18 UA UA2002086809A patent/UA81388C2/en unknown
- 2001-01-18 HR HRP20070360AA patent/HRP20070360B1/en not_active IP Right Cessation
- 2001-01-18 UA UAA200612100A patent/UA89180C2/en unknown
- 2001-03-21 SA SA01210754A patent/SA01210754B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA81388C2 (en) | 2008-01-10 |
| UA89180C2 (en) | 2010-01-11 |
| HRP20070360A2 (en) | 2008-12-31 |
| AR035633A1 (en) | 2004-06-23 |
| SA01210754B1 (en) | 2007-02-17 |
| JO2334B1 (en) | 2006-06-28 |
| PE20011051A1 (en) | 2001-10-17 |
| HRP20070360B1 (en) | 2014-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MEP38008A (en) | Drospirenone for hormone replacement therapy | |
| US6747019B2 (en) | Low dose estrogen interrupted hormone replacement therapy | |
| AR031563A1 (en) | A PHARMACEUTICAL COMPOSITION FOR EMPLOYMENT IN THE TREATMENT OF MENOPAUSIC OR POSMENOPAUSIC DISORDERS OF STROGENS AND MEDROXIPROGESTERONE ACETATE, A PHARMACEUTICAL DOSAGE UNIT AND USE OF A CONJUGATED STRAGEN COMBINATION OF UTROGRAPHIC MANIFORM | |
| EP1482948B1 (en) | Continuous sulfatase inhibiting progestogen hormone replacement therapy | |
| KR20090080989A (en) | Use of estradiol valerate or 17β-estradiol in combination with dienogest for oral therapy for the maintenance and / or increase in female libido | |
| HRP20070188B1 (en) | PHARMACEUTICAL COMBINATION OF ETHINYLESTRADIOL AND DROSPIRENONE FOR USE AS A CONTRACEPTIC | |
| HU221169B1 (en) | Use of estrogen and antiprogestin for producing pharmaceutical compositions useful in hormon replacement therapy and kit containing the same | |
| ES2399105T3 (en) | Quadriphasic estrogen contraceptive continuously graduated | |
| CA2487268A1 (en) | Treatment of post-menopausal complaints in breast cancer patients comprising tibolone and a serm | |
| KR101075929B1 (en) | Composition comprising a combination of an aromatase inhibitor a progestin and an oestrogen and its use for the treatment of endometriosis | |
| CO5590926A2 (en) | USE OF ANASTROZOL FOR THE TREATMENT OF POSMENOPAUSIC WOMEN WHO HAVE A BREASTFUL CANCER | |
| HRP20020258B1 (en) | PHARMACEUTICAL COMBINATION OF ETHINYLESTRADIOL AND DROSPIRENONE FOR USE AS CONTRACEPTIVE | |
| CO5280075A1 (en) | DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY | |
| US6245812B1 (en) | Treatment of hot flashes (flushing) using leucine alone or in combination with other branched chain amino acids | |
| ES2320662T3 (en) | RESTITUTIVE HORMONOTHERAPY AND TREATMENT FOR DEPRESSION WITH DIENOGEST. | |
| ES2230711T3 (en) | COMBINATIONS OF ENDOMETRIAL CONSERVATION PROGESTINES AND ENDOMETRIAL ATROPHY PROGESTINES WITH STROGENS, IN ORAL ANTI-CONCEPTION. | |
| ES2260792T3 (en) | SEQUENTIAL COMBINATION OF A STROGEN AND A PROGESTERONE ANTAGONIST FOR THERAPY THROUGH HORMONE REPLACEMENT. | |
| ES2316402T3 (en) | MESOPROGESTAGENOS (MODULATORS OF PROGESTERONE RECEPTORS) AS A COMPONENT COMPONENT FOR RESTITUTIVE HORMONOTHERAPY (HRT). | |
| AR043470A2 (en) | A PHARMACEUTICAL COMPOSITION TO BE USED AS AN CONTRACEPTIVE | |
| Moghadam et al. | Advances in menopausal hormonal therapy delivery systems: a comparative review | |
| TH2001005863A (en) | Compounds and their uses to relieve symptoms associated with menopause | |
| Panay et al. | Pulsed estrogen therapy: a new concept in hormone replacement therapy | |
| HRP20020666A8 (en) | Drospirenone for hormone replacement therapy | |
| JO2213B1 (en) | A pharmaceutical composition for use as a contraceptive | |
| UY26539A1 (en) | DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |